[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"childhood-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:childhood-cancer":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,35,0,25,[9,47,69,101,125,157,185,207,235,261,284,307,332,358,388,424,451,472,501,523,548,571,598,623,647],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":21,"targetDuration":24,"studyType":25,"phases":4,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100308570","swiss-childhood-cancer-survivor-study-100308570",false,"NCT03297034","Swiss Childhood Cancer Survivor Study","Swiss Childhood Cancer Survivor Study (SCCSS)","SCCSS","Inclusion Criteria:\n\n* Who were diagnosed with cancer at age \\\u003C20 years\n* Who have survived at least 5 years after cancer diagnosis\n* Who were Swiss residents when they were diagnosed, and\n* Who gave informed consent",true,"ALL","5 Years",{"count":22,"type":23},4136,"ESTIMATED","50 Years","OBSERVATIONAL","The SCCSS is designed to investigate which long-term effects childhood cancer and its treatment have on survivors, and includes those who were under 20 years when they were diagnosed. The SCCSS explores childhood cancer survivors' quality of life, the health care received by childhood cancer survivors during follow-up care, the effects of medication, somatic and psychosocial health issues, how childhood cancer survivors take care of their own health including health behaviors, and also collects demographic details like family background, education and profession. To learn more about these topics, the investigators send questionnaires to childhood or adolescent cancer survivors. The investigators use the results to inform physicians and patients, and to improve treatment of childhood cancer and follow-up.",[28],"Childhood Cancer",[30,31,32,33],"Late effects","Childhood cancer survivors","Swiss Childhood Cancer Registry","Europe","RECRUITING","2026-06-24",{"date":37,"type":38},"2026-06-29","ACTUAL",{"date":40,"type":38},"2007-01-01",{"date":42,"type":23},"2050-01",{"name":44,"class":45},"University of Bern","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":46},"100109104","protocol-for-collecting-data-on-patients-with-childhood-cancer-100109104","NCT00684580","Protocol For Collecting Data On Patients With Childhood Cancer","Inclusion Criteria:\n\n* All St Jude patients actively being followed or treated for childhood cancer\n\nExclusion Criteria:\n\n* St. Jude consult only patients\n* St. Jude patients permanently discharged from care and follow-up Permanently discharged patients include patients who have electively transferred their oncologic care to another institution, those who are noncompliant with recommended follow-up or those leaving the institution against medical advice.\n* Patients referred to St. Jude for limited care on phase 1 protocol.",{"count":54,"type":23},30000,"Progress in the development of curative therapy for pediatric malignancies has resulted in increasing numbers of long-term childhood cancer survivors. This protocol is a means to provide continuing review of outcome and late toxicity for all patients actively being treated and previously treated for childhood cancer at St. Jude Children's Research Hospital.",[28],[58,59],"St. Jude Alumni","St. Jude Life Participants","2026-06-15",{"date":62,"type":38},"2026-06-17",{"date":64,"type":38},"2000-06-08",{"date":66,"type":23},"2045-05",{"name":68,"class":45},"St. Jude Children's Research Hospital",{"id":70,"slug":71,"hasResults":12,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":12,"sex":19,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":46},"100484016","patients-at-risk-for-sensory-screening-hparss-to-enhance-sensory-deficit-screening-in-childhood-cancer-survivors-100484016","NCT05582551","Patients At Risk for Sensory Screening (HPARSS) to Enhance Sensory Deficit Screening in Childhood Cancer Survivors","Highlighting Patients At Risk for Sensory Screening (HPARSS) to Enhance Sensory Deficit Screening in Childhood Cancer Survivors","Inclusion Criteria:\n\n* Patients with a diagnosis of pediatric cancer (diagnosis at \\\u003C18 years of age)\n* Treatment including chemotherapy and\u002For radiation therapy\n* Completion of all cancer therapy for at least 6 months and less than 2 years\n* Followed in the Division of Pediatric Hematology\u002FOncology Program at the Washington University School of Medicine\n* Current age between 7 and 17 years of age (age where all of the screening tests are both valid and have been successfully performed by our group)\n* English speaking\n\nExclusion Criteria:\n\n* Undergoing active cancer treatment\n* Patient under the care of the Late Effects Program at St. Louis Children's Hospital\n* Received previous diagnostic testing or rehabilitative therapy for a secondary deficit eligible for screening.\n* Parents and\u002For patient illiteracy\n* No contact with treatment team in the past two years\n* In foster care or without a legal guardian","7 Years","17 Years",{"count":79,"type":23},146,"INTERVENTIONAL",[82],"NA","The overall goal of this study is to attempt to overcome the organizational barriers that impede prompt screening for at-risk sensory deficits in childhood cancer survivors (CCS). Using a cross sectional design study, collaborators in the Informatics Research branch of the Institute of Informatics at the Washington University School of Medicine will identify CCS at risk for sensory deficits based upon their therapy exposure to generate the highlighting patients at risk for sensory screening (HPARSS) document. The investigators will utilize the HPARSS that will link therapy related risks for sensory deficits to specific screening procedures prompting the primary oncology provider to implement screening, diagnostic testing, and therapy.",[28],[86,87,88,89,90,91,92],"childhood cancer survivors","electronic medical record","sensory deficit screening","hearing loss","peripheral neuropathy","vestibular","vision","2026-06-12",{"date":60,"type":38},{"date":96,"type":38},"2023-08-02",{"date":98,"type":23},"2027-05-31",{"name":100,"class":45},"Washington University School of Medicine",{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":80,"phases":109,"briefSummary":110,"conditions":111,"keywords":114,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":124},"100594424","light-therapy-for-chemotherapy-induced-peripheral-neuropathy-in-childhood-cancer-survivors-100594424","NCT07019259","Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors","Inclusion Criteria:\n\n* History of childhood cancer (\\\u003C21 years of age at diagnosis)\n* Current age five years or older (due to availability of validated measures for CIPN in this age group)\n* History of exposure to vinca alkaloid, platinum, or other chemotherapeutic agent that can cause CIPN\n* CIPN as assessed by a trained physical therapist defined as a score of four or higher on the ped-mTNS (for survivors \\\u003C18 years old at evaluation), or the mTNS (for survivors 18 years or older at evaluation)\n\nExclusion Criteria:\n\n* Currently Pregnant or lactating (by patient report, at initiation or at any point of the study)\n* Inability to sit still for at least 15 minutes\n* Diagnosis of neuropathy prior to cancer treatment\n* Active cancer diagnosis or cancerous skin lesion\n* Central nervous system tumor (due to lack of validated measures for CIPN in this population)\n* Cancer lesion or open wound in the area to be treated, or any condition that can potentially be made worse by the correct or incorrect use of the device.",{"count":108,"type":23},20,[82],"The purpose of this study is to determine feasibility and acceptability of a six-week at-home light therapy protocol in childhood cancer survivors, to identify facilitators and barriers to implementing this intervention, and to measure signs and symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN) at baseline and following completion of the at-home light therapy protocol.",[112,28,113],"Cancer","Chemotherapy-induced Peripheral Neuropathy",[115],"Survivors of childhood cancer","2026-06-11",{"date":93,"type":38},{"date":119,"type":38},"2025-06-30",{"date":121,"type":23},"2027-04",{"name":123,"class":45},"Yale University",2,{"id":126,"slug":127,"hasResults":12,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":12,"sex":19,"minAge":133,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":80,"phases":137,"briefSummary":140,"conditions":141,"keywords":142,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":156},"100497253","phase-1-cannabinoids-in-pediatric-oncology-100497253","NCT05754840","CANnabinoids in Pediatric ONCology","A Randomized, Double-Blind Tolerability Trial of Cannabinoids for Symptom Management in Children With Cancer: the CAN-PONC Trial","CAN-PONC","Inclusion Criteria:\n\n1. Ages 4-17 years old at the time of enrollment\n2. Diagnosed with relapsed or refractory solid or hematologic malignancy including brain tumours\n3. Currently receiving active cancer treatment or supportive and palliative care\n4. Estimated survival of at least 4 months at the time of enrollment\n\nExclusion Criteria:\n\n1. History of cardiovascular disease, severe hepatic or renal impairment defined by alanine transaminase (ALT)\u002F aspartate aminotransferase (AST) more than 5x upper limit of normal (ULN), creatinine more than 5x ULN or glomerular filtration rate (GFR less than) \\\u003C60 mL\u002Fmin\u002F1.73 m273m2, unstable\u002Funmanaged arrhythmias, uncontrolled hypertension with blood pressure above 99th centile for age or history of myocardial infarction\n2. Nabilone or other cannabis-based products use (including for recreational purposes) within the past 2 weeks or planned nabilone use for the duration of their enrollment in the trial. Current use\u002Fcontinued use of recreational cannabis, or not willing to abstain from recreational cannabis use during the trial\n3. Anyone who is pregnant or breast\u002Fchest-feeding throughout the duration of the study or has the intention to become pregnant within 3 months of study completion\n4. Participation in other clinical trials that prohibit the concurrent use of cannabis\n5. Children with a personal or family history of schizophrenia or psychotic disorders, substance use disorder or allergy to cannabinoids or cannabis\n6. Unwilling or unable to use effective form of contraception and refrain from driving motorized vehicles (cars, motorcycles, boats, etc.) throughout the study period\n7. Anyone who is currently receiving cell therapies or immune checkpoint inhibitors","4 Years","18 Years",{"count":136,"type":23},60,[138,139],"PHASE1","PHASE2","CANnabinoids in Pediatric ONCology is a randomized, double blind, adaptive clinical trial looking at the tolerability of cannabinoids in children with cancer across 3 Canadian children's hospitals.",[28,112],[143,144,145,146,147],"cannabinoids","CBD","THC","pediatrics","cannabis","2026-06-09",{"date":116,"type":38},{"date":151,"type":38},"2025-07-18",{"date":153,"type":23},"2026-12-31",{"name":155,"class":45},"University of Manitoba",3,{"id":158,"slug":159,"hasResults":12,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":12,"sex":19,"minAge":134,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":167,"conditions":168,"keywords":171,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":184},"100346454","cardiac-dysfunction-in-childhood-cancer-survivors-100346454","NCT03790943","Cardiac Dysfunction in Childhood Cancer Survivors","Prospective Single Center Cohort Study for Early Detection of Cardiac Dysfunction in Childhood Cancer Survivors","Cardio-Onco","This prospective cohort study is nested within the Childhood Cancer Registry (ChCR), a national, population-based cancer registry that includes all children and adolescents in Switzerland who were diagnosed with cancer at age 0-20 years. It includes patients diagnosed with leukemia, lymphoma, central nervous system tumors, and malignant solid tumours or Langerhans cell histiocytosis. Childhood cancer survivors have survived at least 5 years from cancer diagnosis.\n\nInclusion Criteria:\n\n* Registered in the ChCR\n* Formerly treated at the Department of Pediatric Hematology\u002FOncology of one of five participating centers\n* Treated with any chemotherapy and\u002For chest radiation\n* Survived ≥ 5 years since most recent cancer diagnosis (primary cancer, relapse(s), secondary cancer) at time of examination\n* Diagnosed at age ≤ 20 years\n* ≥ 18 years of age at time of study participation\n* Resident in Switzerland\n* Written informed consent\n\nExclusion Criteria:\n\n* Study participants will be excluded if they do not meet the above mentioned inclusion criteria or refuse to participate in the study.",{"count":166,"type":23},500,"This multicenter, prospective cohort study evaluates early cardiac dysfunction in adult survivors of childhood cancer. The hypothesis of this study is that cardiac dysfunction can be detected earlier when using speckle tracking echocardiography as novel echocardiographic technique compared to conventional echocardiography.",[169,170,28],"Cardiac Dysfunction","Cardiovascular Diseases",[31,30,172,173,174,175],"Cardiotoxicity","Chemotherapy","Anthracyclines","Radiation","2026-05-27",{"date":178,"type":38},"2026-05-29",{"date":180,"type":38},"2018-02-13",{"date":182,"type":23},"2029-04-23",{"name":44,"class":45},6,{"id":186,"slug":187,"hasResults":12,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":12,"sex":191,"minAge":192,"maxAge":134,"enrollmentInfo":193,"targetDuration":4,"studyType":80,"phases":195,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":156},"100299658","male-fertility-preservation-using-cryopreservation-of-testicular-tissue-before-highly-gonadotoxic-cancer-treatment-100299658","NCT03180918","Male Fertility Preservation Using Cryopreservation of Testicular Tissue Before Highly Gonadotoxic Cancer Treatment","Inclusion Criteria:\n\n* Prepubertal patients aged 3 months and older\n* Peri and pubertal patients after failure of sperm cryopreservation\n* Patients presenting high risk of infertility because of gonadotoxic treatments (i.e high dose of alkylating agents, testicular irradiation, total body irradiation).\n* Multidisciplinary team consensus in favour of proposition to cryopreserve testicular tissue\n\nExclusion Criteria:\n\n* Patients under the age of 3 months\n* Refusal of the patient and\u002For his parents\n* Treatments that are not highly gonadotoxic","MALE","3 Months",{"count":194,"type":23},100,[82],"Background:\n\nDue to the remarkable improvement in treatments these last decades, long term survival can be expected in more than 80% of childhood cancer patients. Unfortunately, cancer treatments can be harmful to the gonads and can affect reproductive and endocrine functions. While loss of fertility is a major concern for most patients, sperm cryopreservation should be offered to all pubertal male patients. For prepubertal boys, only the experimental option of testicular biopsy in order to cryopreserve testicular stem cells can be proposed.\n\nPrimary aims\n\n\\- To cryopreserve testicular tissue of prepubertal patient receiving highly gonadotoxic oncological treatment.\n\nSecondary aims\n\n* To cryopreserve testicular tissue after failure of sperm cryopreservation in pubertal patient with high risk of infertility\n* To create a database in order to record clinical and biological follow-up data\n* To create a research biobank for future research projects\n\nMulticentric study: HUG, CHUV, UKBB",[28,198],"Fertility Disorders","2026-05-21",{"date":176,"type":38},{"date":202,"type":38},"2015-01",{"date":204,"type":23},"2100-01",{"name":206,"class":45},"Gumy-Pause Fabienne",{"id":208,"slug":209,"hasResults":12,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":19,"minAge":214,"maxAge":215,"enrollmentInfo":216,"targetDuration":4,"studyType":80,"phases":218,"briefSummary":219,"conditions":220,"keywords":222,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":234},"100512889","heuristic-tool-to-improve-symptom-self-management-in-adolescents-and-young-adults-with-cancer-100512889","NCT05958316","Heuristic Tool To Improve Symptom Self-Management in Adolescents and Young Adults With Cancer","A Randomized Controlled Trial Using a Heuristic Tool To Improve Symptom Self-Management in Adolescents and Young Adults With Cancer","Inclusion Criteria:\n\n* Has received at least 1 cycle of cancer treatment and is within 3 months of receiving that first cycle of treatment\n* Receiving regularly scheduled cancer treatment and will be receiving at least three more cycles\n* Reports at least 1 symptom related to cancer and\u002For its treatment\n* Able to speak, read, and write English as required for completion of the C-SCAT and study measures\n\nExclusion Criteria:\n\n\\- Cognitive and\u002For physical inability to complete study measures.","15 Years","29 Years",{"count":217,"type":23},126,[82],"Determine the effects of the Computerized Symptom Assessment Tool (C-SCAT) versus usual care on the primary outcomes of self-efficacy for symptom management and symptom self-management behaviors",[221,112,28],"Symptoms and Signs",[223,224],"Supportive Care","Symptom Management","2026-05-20",{"date":227,"type":38},"2026-05-22",{"date":229,"type":38},"2024-01-04",{"date":231,"type":23},"2027-08-31",{"name":233,"class":45},"Virginia Commonwealth University",5,{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":18,"sex":19,"minAge":134,"maxAge":241,"enrollmentInfo":242,"targetDuration":4,"studyType":80,"phases":244,"briefSummary":245,"conditions":246,"keywords":247,"overallStatus":251,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":46},"100638827","comunicar-community-led-family-centered-communication-for-cancer-survivorship-care-100638827","NCT07606443","COMUNICAR: Community-Led Family-Centered Communication for Cancer Survivorship Care","Inclusion Criteria:\n\n1. Childhood cancer survivor previously treated with chemotherapy and\u002For radiation therapy\n2. Currently age 18-25 years\n3. Identifies as Hispanic\u002FLatino\n4. Currently ≥5 years post cancer diagnosis\n5. Fluent in English or Spanish\n6. Receives medical care at Stanford\n7. Lives within Jacob's Heart service area (zip codes within Monterey, Santa Cruz, Santa Clara, San Benito Counties: https:\u002F\u002Fwww.jacobsheart.org\u002Fservice-area)\n8. Ability to understand and the willingness to provide written informed consent.\n\nExclusion Criteria:\n\n1\\. Lack of proficiency in written and spoken English or Spanish","25 Years",{"count":243,"type":23},18,[82],"This study will test a novel intervention to facilitate family-centered communication among Hispanic\u002FLatino (H\u002FL) young adult childhood cancer survivors (YA-CCS), their support persons, and their clinicians through collaboration between the clinic and a community-based organization.",[28],[248,249,250],"cancer","hispanic","young adult","NOT_YET_RECRUITING","2026-05-18",{"date":254,"type":38},"2026-05-26",{"date":256,"type":23},"2026-07",{"date":258,"type":23},"2028-07",{"name":260,"class":45},"Stanford University",{"id":262,"slug":263,"hasResults":12,"nctId":264,"briefTitle":265,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":18,"sex":19,"minAge":134,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":80,"phases":268,"briefSummary":269,"conditions":270,"keywords":272,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":46},"100579067","imaging-skeletal-muscle-mitochondrial-oxphos-activity-in-acute-lymphoblastic-leukemia-survivors-100579067","NCT06819475","Imaging Skeletal Muscle Mitochondrial OXPHOS Activity In Acute Lymphoblastic Leukemia Survivors","Inclusion Criteria:\n\n* Survivor- or Control-Participant is age 18 years old or older at time of consent and enrolled in SJLIFE.\n* Survivor- Participant is childhood ALL survivor\n* Survivor- or Control Participant has low muscle mass as defined by relative lean mass z-score of less than or equal to -0.5 SD (lean mass divided by height in meters squared).\n* Survivor - Participant is able and willing to give informed consent\n\nExclusion Criteria:\n\n* Survivor-Participant has history of cranial radiation.\n* Survivor- or Control-Participant has implanted medical devices or metal that would interfere with MRI or MRS\n* Female Survivor- or Control-Participant is pregnant.\n* Survivor- or Control-Participant is taking anticoagulants (e.g. aspirin, apixaban, coumadin, edoxaban, rivaroxaban)\n* Survivor- or Control-Participant weighs more than 300 pounds.\n* Survivor- or Control-Participant is allergic to local anesthetic (i.e., lidocaine, bupivacaine).\n* Survivor- or Control-Participant cannot lie flat on his\u002Fher back for 90 minutes or longer\n* Survivor- or Control-Participant has a current history of peripheral motor neuropathy.",{"count":136,"type":23},[82],"The participants are being asked to take part in this trial, because the participant is a survivor of childhood cancer or agreed to be part of a volunteer group to understand the relation between cancer and cancer treatment and muscle weakness in survivors of Acute Lymphoblastic Leukemia (ALL). ALL is cancer of the blood and bone marrow.\n\nPrimary Objective\n\n• To compare muscle mtOXPHOS activity and satellite cell content among ALL survivors and controls.\n\nSecondary Objective\n\n* To evaluate the association between muscle mtOXPHOS, muscle satellite cell content and physical performance in ALL survivors.\n* To evaluate the association of muscle morphology and epigenetics with muscle mtOXPHOS in ALL survivors.",[28,271],"Muscle Weakness",[273,274,275,19,276],"Survivor","Acute Lymphoblastic Leukemia","Adult","Healthy Volunteer","2026-05-14",{"date":252,"type":38},{"date":280,"type":38},"2025-06-02",{"date":282,"type":23},"2028-01",{"name":68,"class":45},{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":12,"sex":19,"minAge":134,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":80,"phases":292,"briefSummary":293,"conditions":294,"keywords":295,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":46},"100573563","assessment-of-remote-approaches-for-identification-of-autonomic-dysfunction-among-survivors-of-leukemia-and-lymphoma-100573563","NCT06747910","Assessment of Remote Approaches for Identification of Autonomic Dysfunction Among Survivors of Leukemia and Lymphoma","Inclusion Criteria:\n\n* Participants enrolled in St. Jude Lifetime Cohort (SJLIFE) \\>18 years of age.\n* Primary diagnosis of acute lymphoblastic leukemia (ALL), Hodgkin's Lymphoma (HL), or Non-Hodgkin's Lymphoma (Non-HL).\n* Not currently taking beta-blocker medication.\n\nExclusion Criteria:\n\n* Individuals who cannot speak, read, and\u002For understand English.\n* Individuals who are unable to follow directions\u002Finstructions in order to complete the Ewing battery.\n* Individuals with acute heart failure (new or worsening signs and symptoms of heart failure, including a combination of the following: dyspnea, orthopnea, lower limb swelling, elevated jugular venous pressure, and pulmonary congestion).\n* Women who are currently pregnant.",{"count":291,"type":23},188,[82],"This study seeks to determine if diagnosing cardiac autonomic dysfunction (AD) can be done remotely with the same accuracy as in-person testing. If so, the identification of AD could happen sooner, facilitating remote studies of the condition and potentially reducing the risk of illness. Childhood cancer survivors, particularly survivors of acute lymphoblastic leukemia (ALL) and Hodgkins's lymphoma (HL), appear to be at increased risk for AD.\n\nPrimary Objectives:\n\n* To determine the sensitivity and specificity of heart rate variability (HRV), measured remotely with biosensor technology (Actigraph LEAP), compared to in-person assessment using the Ewing battery as the reference standard to identify cardiac autonomic dysfunction (AD) among survivors of leukemia and lymphoma.\n* To determine the sensitivity and specificity of the Composite Autonomic Symptom Scale 31 (COMPASS31) compared to the Ewing battery to identify AD among leukemia and lymphoma survivors.",[28],[273,296,297,298],"Acute lymphoblastic leukemia","Hodgkins's lymphoma","Autonomic","2026-04-22",{"date":301,"type":38},"2026-04-23",{"date":303,"type":38},"2025-02-03",{"date":305,"type":23},"2026-06",{"name":68,"class":45},{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":12,"sex":19,"minAge":4,"maxAge":134,"enrollmentInfo":314,"targetDuration":4,"studyType":80,"phases":316,"briefSummary":317,"conditions":318,"keywords":320,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":124},"100562923","proof-of-concept-testing-of-the-cardiovascular-health-equity-through-food-chef-intervention-in-childhood-cancer-survivors-100562923","NCT06609473","Proof-of-Concept Testing of the Cardiovascular Health Equity Through Food (CHEF) Intervention in Childhood Cancer Survivors","CHEF","Inclusion Criteria:\n\n* Child with any primary cancer diagnosis (non-relapsed, non-secondary malignancy) who has received cancer-directed therapy that includes chemotherapy and\u002For radiation therapy;\n* Child is within one of the following time windows:\n\n  1. Among those receiving chemotherapy, any time from start of last planned cycle of chemotherapy until 12 months from completion of chemotherapy;\n  2. Among those receiving radiation therapy alone or radiation and surgery, any time from completion of radiation until 12 months post completion;\n* Child has 1 or more cardiovascular risk factor (defined as any of: body mass index ≥ 85th percentile; systolic or diastolic blood pressure ≥90th percentile; dyslipidemia \\[triglycerides ≥150 mg\u002FdL, total cholesterol ≥200 mg\u002FdL, LDL cholesterol ≥130 mg\u002FdL, HDL cholesterol ≤40 mg\u002FdL\\]; impaired glucose metabolism \\[fasting glucose ≥100 mg\u002FdL, hemoglobin A1c ≥5.7%\\]; anthracycline exposure ≥100 mg\u002Fm2; or any radiation exposure to chest, brain, thoracic spine, or total body);\n* Child is ≤18 years of age at time of enrollment, or over 18 years of age but under medical guardianship;\n* Parent\u002Fguardian screened positive for food insecurity.\\* \\*Assessed through validated 2-item food insecurity screen.\n\nExclusion Criteria:\n\n* Patient received only surgery, or watchful waiting\u002Fsurveillance, for cancer- directed therapy;\n* Foreign national family receiving cancer care as an embassy-pay patient.",{"count":315,"type":23},17,[82],"The goal of the Cardiovascular Health Equity Through Food (CHEF) program is to make it easier for participants and families to cook and eat healthy foods during and following childhood cancer treatment with the long-term goal of supporting heart health.",[28,319],"Childhood Cancer Survivors",[321,28,322],"Cardiovascular Health","Childhood Cancer Survivorship","2026-04-08",{"date":325,"type":38},"2026-04-13",{"date":327,"type":38},"2025-04-07",{"date":329,"type":23},"2028-03-30",{"name":331,"class":45},"Dana-Farber Cancer Institute",{"id":333,"slug":334,"hasResults":12,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":338,"eligibilityCriteria":339,"healthyVolunteers":12,"sex":19,"minAge":340,"maxAge":241,"enrollmentInfo":341,"targetDuration":4,"studyType":80,"phases":342,"briefSummary":343,"conditions":344,"keywords":4,"overallStatus":251,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":4},"100624340","early-diagnosis-and-cardiovascular-risk-stratification-in-children-exposed-to-cancer-therapies-100624340","NCT07408362","Early Diagnosis and Cardiovascular Risk Stratification in Children Exposed to Cancer Therapies","How to Improve Early Diagnosis and Cardiovascular Risk Stratification in Children Exposed to Chemotherapy and\u002For Thoracic Radiotherapy? Multimodal Cardiological Evaluation and Biomarkers.","CTRCT-pedia","Inclusion Criteria:\n\n* History of chemotherapy and\u002For radiotherapy for an oncological condition or bone marrow transplantation (hematologic disease) after 01\u002F01\u002F2016.\n* Age \\\u003C 18 years at the time of treatment.\n* Cancer remission for more than one year.\n* Voluntary participation following comprehensive informed consent.\n* Signed informed consent from the patient (≥ 18 years) or from parents\u002Flegal guardians, with signed assent for minors aged 8 to 17.\n\nExclusion Criteria:\n\n* Active disease recurrence or relapse.\n* Current administration of antineoplastic therapy.\n* Withdrawal of consent or refusal to participate by the patient or their legal representatives.","2 Years",{"count":194,"type":23},[82],"The goal of this prospective interventional study is to improve the detection of subclinical chronic Cancer Therapy-Related Cardiovascular Toxicity (CTRCT) and evaluate the added value of advanced cardioechography, ergospirometry, and specific biomarkers in pediatric cancer survivors (aged 2 to 25) who received potentially cardiotoxic treatments (chemotherapy\u002Fthoracic radiotherapy). The main questions it aims to answer are:\n\n* Can advanced echocardiography (including strain and myocardial work), ECG, and ergospirometry effectively diagnose earlier subclinical cardiac impairment in this population?\n* What is the prevalence of cardiovascular risk factors (including physical activity levels and biological markers like proBNP\u002Ftroponins)\n* Can new genetic or biological markers be identified to help optimizing the detection of CTRCT?\n\nAt time of follow-up, if they agree, participants will:\n\n* Complete validated questionnaires regarding quality of life, physical activity, and sedentary behavior.\n* Undergo a cardiopulmonary exercise test (ergospirometry) for those aged over 8 years.\n* Wear an accelerometer (ActiGraph GT3X) for 7 consecutive days to monitor physical activity.\n* Provide an additional blood sample during routine follow-up for the creation of a biobank dedicated to analyzing markers of senescence, fibrosis, apoptosis, and genetic polymorphisms.",[345,28,346,347,348],"Cancer Therapy-related Cardiovascular Toxicity","Chemotherapeutic Toxicity","Radiotherapy Side Effect","Cardiovascular Complication","2026-02-10",{"date":351,"type":38},"2026-02-13",{"date":353,"type":23},"2026-02-15",{"date":355,"type":23},"2033-12-31",{"name":357,"class":45},"Centre Hospitalier Universitaire de Liege",{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":18,"sex":19,"minAge":4,"maxAge":77,"enrollmentInfo":366,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":368,"conditions":369,"keywords":372,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":46},"100622310","biomarkers-of-brain-injury-in-children-with-brain-tumors-100622310","NCT07381959","Biomarkers of Brain Injury in Children With Brain Tumors","Biomarkörer för hjärnskada Hos Barn Med hjärntumör","BiomarkCBT","Inclusion Criteria, Group A (treated with radiation):\n\n* Age 0-17 years old, AND\n* Diagnosed with primary brain tumor through surgery, biopsy, or other diagnostic method (e.g., for germinoma) at Uppsala University Hospital or at another university hospital in Sweden, AND\n* Referred for radiotherapy at Skandion Clinic in Uppsala and\u002For at their local hospital (in some cases), with\u002Fwithout the addition of other cancer treatments.\n\nInclusion Criteria, Group B (treated without radiation\u002Fradiation naive):\n\n* Age 0-17 years old, AND\n* Diagnosed with primary brain tumor through surgery, biopsy, or other diagnostic method (e.g., for optic pathway glioma in neurofibromatosis type 1 and germinoma) at Uppsala University Hospital or at another university hospital in Sweden, AND\n* Not referred to radiotherapy and treated with\u002Fwithout the addition of other cancer treatments.\n\nInclusion Criteria, Group C (healthy control group):\n\n* Age 0-17 years old at time of recruitment\n\nExclusion Criteria, Groups A + B:\n\n* Diagnosed with a tumor only in the spinal cord (solitary spinal tumor).\n* Diagnosed with a tumor considered palliative already at diagnosis (e.g., diffuse intrinsic pontine glioma)\n\nExclusion Criteria, Group C:\n\n* Have diagnosis of chronic disease that requires continuous medication.\n\nExclusion Criteria, all groups:\n\n* Unable to provide informed consent due to language difficulties.",{"count":367,"type":23},560,"The goal of this observational study is to identify biomarkers of treatment-induced brain injury in children treated for primary brain tumors. The main question it aims to answer is:\n\nCan investigators identify sensitive plasma biomarker(s) of treatment-induced brain injury in children with primary brain tumors?\n\nResearchers will compare results between different treatment modalities (surgery, chemotherapy, radiation versus radiation-naive) and a healthy age- and sex-matched control population, to identify treatment-specific biomarkers.\n\nParticipants will provide plasma samples at the following time points: before surgery, 1-2 weeks after surgery, as well as at 3-, 6-, 12-, 18-, 24-, and 36 months after surgery. Participants who receive radiation treatment will also provide plasma samples before and during treatment (approximately every 2 weeks). Where possible, plasma samples are also collected before the start of any new treatment (e.g., chemotherapy). Healthy controls will provide samples once.",[370,28,371],"Brain Tumor","Childhood Brain Tumor",[373,374,375,376,377,378],"Radiotherapy","Cranial radiation therapy","Plasma biomarkers","Extracellular vesicles","Proteomics","Childhood brain tumor","2026-01-28",{"date":381,"type":38},"2026-02-02",{"date":383,"type":38},"2021-08-01",{"date":385,"type":23},"2031-12-31",{"name":387,"class":45},"Uppsala University",{"id":389,"slug":390,"hasResults":12,"nctId":391,"briefTitle":392,"officialTitle":392,"acronym":4,"eligibilityCriteria":393,"healthyVolunteers":12,"sex":19,"minAge":394,"maxAge":395,"enrollmentInfo":396,"targetDuration":4,"studyType":80,"phases":398,"briefSummary":399,"conditions":400,"keywords":404,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":423},"100532119","phase-1-optimal-precision-therapies-to-customise-care-in-childhood-and-adolescent-cancer-100532119","NCT06208657","Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer","Inclusion Criteria:\n\n1. Patients must be diagnosed with a solid tumor, CNS tumor or lymphoma that has progressed despite standard therapy, or for which no effective standard therapy exists.\n2. Age \\\u003C21 years at inclusion; patients 21 years and older may be included after approval by the Study Chair if they have a pediatric type recurrent\u002Frefractory malignancy.\n3. Patients must be enrolled on a precision medicine study (i.e. PROFYLE, ZERO or equivalent as agreed with Study Chair).\n4. Patients enrolled in a Phase I cohort must have either evaluable or measurable disease.\n5. Patients enrolled in a Phase II cohort must have measurable disease. Evaluable and measurable disease are defined by standard imaging criteria for the patient's tumor type.\n6. Disease evaluations, laboratory tests, and other clinical assessments that are considered standard of care may be undertaken at the patient's local oncology treatment centre with results transferred to study site for evaluation.\n7. Performance status: Karnofsky performance status (for patients \\> 16 years of age) or Lansky play score (for patients ≤ 16 years of age) ≥ 50%.\n8. Life expectancy ≥ 6 weeks.\n9. Patients must have fully recovered from the acute toxic effects of all prior anticancer therapy and must meet the following minimum duration from prior anticancer-directed therapy prior to enrolment.\n10. Adequate organ function.\n11. Able to comply with scheduled follow-up and with management of toxicity.\n12. Females of childbearing potential must have a negative serum or urine pregnancy test.\n13. Fertile males must agree to use adequate contraception during the study and following completion of treatment.\n14. Provide a signed and dated informed consent form.\n\nExclusion Criteria:\n\n1. Patients with symptomatic central nervous system (CNS) primary or metastatic tumours who are neurologically unstable or require increasing doses of corticosteroids or local CNS-directed therapy to control their CNS disease. Patients on stable doses of corticosteroids for at least 7 days prior to receiving study drug may be included.\n2. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter drug absorption of oral drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhoea, or malabsorption syndrome) - only for arms that include orally administered therapeutic agents.\n3. Clinically significant, uncontrolled heart disease (including history of any cardiac arrhythmias, e.g., ventricular, supraventricular, nodal arrhythmias, or conduction abnormality), unstable ischemia, congestive heart failure within 12 months of screening.\n4. Known active viral hepatitis or human immunodeficiency virus (HIV) infection or any other uncontrolled infection.\n5. Major surgery within 21 days of the first dose of investigational drug. Gastrostomy, ventriculo-peritoneal shunt, endoscopic ventriculostomy, tumour biopsy and insertion of central venous access devices are not considered major surgery, but for these procedures, a 48-hour interval must be maintained before the first dose of the investigational drug is administered.\n6. Known hypersensitivity to any study drug or component of the formulation.\n7. Pregnant or nursing (lactating) females.\n8. Any other concomitant serious medical condition or organ dysfunction that in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety of the investigational drug(s).","0 Years","21 Years",{"count":397,"type":23},90,[138,139],"A companion platform trial to test novel targeted agents based on the patient's tumor profile.",[28,401,371,402,403],"Childhood Solid Tumor","Recurrent Cancer","Refractory Cancer",[405,406,407,408,409,410,411,412,413,414],"children","basket trial","platform study","pediatric","solid tumor","paediatric","solid tumour","CNS tumor","CNS tumour","lymphoma","2026-01-26",{"date":379,"type":38},{"date":418,"type":38},"2024-07-10",{"date":420,"type":23},"2035-12",{"name":422,"class":45},"Australian & New Zealand Children's Haematology\u002FOncology Group",14,{"id":425,"slug":426,"hasResults":12,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":4,"eligibilityCriteria":430,"healthyVolunteers":18,"sex":19,"minAge":134,"maxAge":4,"enrollmentInfo":431,"targetDuration":433,"studyType":25,"phases":4,"briefSummary":434,"conditions":435,"keywords":4,"overallStatus":251,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":4},"100616645","examination-of-the-relationship-between-quality-of-life-and-caregiving-burden-among-caregivers-of-pediatric-oncology-patients-100616645","NCT07308301","Examination of the Relationship Between Quality of Life and Caregiving Burden Among Caregivers of Pediatric Oncology Patients","EXAMİNATİON OF THE RELATİONSHİP BETWEEN QUALİTY OF LİFE AND CAREGİVİNG BURDEN AMONG CAREGİVERS OF PEDİATRİC OCOLOGY PATİENTS","Inclusion Criteria:\n\n* Being a family member who provides care for a child aged 0-18 years diagnosed with cancer\n* The child being in the active treatment phase (chemotherapy, radiotherapy, post-surgical follow-up, etc.)\n* Being able to read and write in Turkish and having sufficient literacy to complete the research questionnaire\n* Willingness to participate in the study\n\nExclusion Criteria:\n\n* Not being the primary caregiver of the child (serving only as a short-term companion)\n* Being unable to complete the questionnaire due to a psychiatric diagnosis or communication difficulties\n* The child having a disability",{"count":432,"type":23},95,"4 Months","Primary Aim\n\nThe primary aim of this study is to determine the quality of life and caregiving burden levels of caregivers of pediatric oncology patients and to examine the relationship between these two variables.\n\nSecondary Aims\n\nTo evaluate the differences between caregivers' sociodemographic characteristics (age, gender, education level, marital status, income level, etc.) and their quality of life.\n\nTo examine the differences between caregivers' sociodemographic characteristics and their caregiving burden levels.\n\nTo determine whether caregivers' quality of life and caregiving burden differ according to the diagnosis and treatment characteristics of pediatric oncology patients (duration of diagnosis, type of treatment, frequency of hospitalization, etc.).\n\nSignificance of the Study\n\nChildhood cancer is a process that deeply affects not only the patient but also the family, particularly the caregivers. Family members who provide care for children often face intense physical, psychological, social, and economic burdens. These challenges reduce caregivers' quality of life and increase their caregiving burden.\n\nIdentifying the relationship between the quality of life and caregiving burden among caregivers of pediatric oncology patients is highly important in planning support services for families during the care process and in strengthening family-centered care practices by healthcare professionals.\n\nThe findings of this study will contribute to the development of family-centered approaches in nursing care, the design of psychosocial support programs, and a better understanding of caregivers' needs.",[28,436,437,438,439,440,441],"Childhood Cancers","Caregiver Subjective Burden","Primary Caregivers of Children Newly Diagnosed With Cancer","Caregiver","Caregiver Anxiety","Caregiver Health Related QOL","2025-12-26",{"date":444,"type":38},"2025-12-31",{"date":446,"type":23},"2026-01-01",{"date":448,"type":23},"2026-06-30",{"name":450,"class":45},"Fatma Beyza Akdeniz",{"id":452,"slug":453,"hasResults":12,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":4,"eligibilityCriteria":457,"healthyVolunteers":12,"sex":191,"minAge":458,"maxAge":134,"enrollmentInfo":459,"targetDuration":4,"studyType":80,"phases":460,"briefSummary":461,"conditions":462,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":46},"100520975","cryopreservation-of-prepubertal-testicular-tissue-for-preservation-of-fertility-in-young-boys-with-cancer-100520975","NCT06063551","Cryopreservation of Prepubertal Testicular Tissue for Preservation of Fertility in Young Boys With Cancer","Cryopreservation of Prepubertal Testicular Tissue for Preservation","Inclusion Criteria:\n\n* Pre- and peripubertal boys\n* Due to receive cancer treatment that is predicted to have a high risk (\\>80%) of infertility\n* Consent to removal of testicular tissue for storage and research\n* Unable to produce a semen sample by masturbation\n\nExclusion Criteria:\n\n* Participation in study would delay treatment\n* Too unwell to undergo the procedure\n* Pre-existing testicular pathology\u002Fprevious testicular surgery (eg orchidopexy)\n* Able to produce a semen sample for cryopreservation","1 Day",{"count":194,"type":23},[82],"Prepubertal boys treated for cancer are at risk of infertility as a result of their treatment. At present there are no options to preserve fertility in these boys. With informed consent, the investigators aim to cryopreserve (freeze) testis tissue biopsies taken from boys undergoing cancer therapy with a high risk of infertility. A portion of cryopreserved tissue will be securely stored, which in the future may be used to restore fertility in the patients. A second portion of the tissue will be used for laboratory work aimed at understanding the conditions required for development of the germ cells.\n\nPatients will be recruited from the Oncology Department at the Royal Hospital for Children and Young People (RHCYP) in Edinburgh. Tissue will be obtained from prepubertal patients with cancer who are about to undergo treatment with a high risk (\\>80%) of infertility. Informed consent will be obtained from the patients legal guardian (and patient if applicable) for the procedure and subsequent use of tissue. A testis biopsy from one testis will be performed and if possible will coincide with a planned routine procedure requiring general anaesthetic in order to avoid the need for additional anaesthesia.\n\nThe procedure will take place at RHCYP during the initial assessment and prior to the commencement of cancer treatment and will not result in delay of treatment. Tissue will be assessed for the presence of sperm for storage using existing methods. In addition, tissue will be cryopreserved by Tissue and Cells Directorate, SNBTS in Edinburgh. The tissue will be stored for up to 55 years in accordance with current legislation (HFEA Act as amended 2005). Research will be carried out at the MRC Centre for Reproductive Health in accordance with Human Tissue (Scotland) Act 2006.",[198,28],"2025-11-19",{"date":465,"type":38},"2025-11-20",{"date":467,"type":38},"2016-04-01",{"date":469,"type":23},"2061-04",{"name":471,"class":45},"University of Edinburgh",{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":478,"eligibilityCriteria":479,"healthyVolunteers":12,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":480,"targetDuration":4,"studyType":80,"phases":482,"briefSummary":483,"conditions":484,"keywords":485,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":46},"100575211","preparing-for-life-and-academics-for-young-childhood-cancer-survivors-100575211","NCT06769334","Preparing for Life and Academics for Young Childhood Cancer Survivors","Digital Health Intervention to Improve Neurodevelopmental Outcomes for Young Childhood Cancer Survivors in Underserved Communities","PLAY","For the caregiver:\n\n* Caregiver is the legal guardian of the child (e.g., mothers, fathers, grandparents, adoptive parents)\n* Caregiver lives with the child more than 50% of the time\n* Caregiver primary language is English\n* Caregiver lives within 150 miles of Nationwide Children's Hospital\n\nFor the childhood cancer survivor:\n\n* Received treatment for their cancer (e.g., chemotherapy, surgical resection, radiation therapy)\n* Completed cancer treatment or on maintenance therapy only, without evidence of recurrent disease\n* Childhood cancer survivor is currently between the ages of 3 years old to 6 years old, but no older than 6.5 years old at study enrollment\n\nExclusion Criteria for the childhood cancer survivor:\n\n* Has a documented neurodevelopmental disorder prior to their cancer diagnosis (e.g., neurofibromatosis, tuberous sclerosis, Down's syndrome, autism)\n* Did not receive any treatment for their cancer (e.g., chemotherapy, surgical resection, radiation)\n* Treated for a benign tumor\n\nFor the teacher:\n\nClassroom or daycare teacher of the childhood cancer survivor",{"count":481,"type":23},105,[82],"The goal of this clinical trial is to test and improve an online program for caregivers of young childhood cancer survivors called the Preparing for Life and Academics for Young Survivors program (PLAY). The PLAY program was created with a group of caregivers of young children with cancer and healthcare providers. Ultimately, investigators hope to see if the program can improve positive parenting behaviors, reduce caregiver stress, and help get young children ready for school. In the preliminary phase of this clinical trial, investigators are aiming to answer these questions:\n\n1. Are caregivers of childhood cancer survivors willing to participate in the PLAY program and complete assessments before and after the program?\n2. Do caregivers of childhood cancer survivors rate the PLAY program as easy to use?\n3. Are caregivers of childhood cancer survivors satisfied with the PLAY program?\n4. How can the PLAY program be improved in the future?\n5. Does PLAY help improve how caregivers interact and read with their children or how they manage their own stress?\n\nWhen the child is transitioning to maintenance phase therapies or is no longer actively in cancer treatment, caregivers will be invited to participate. If they agree to participate, they will complete surveys when they begin the study as well as a videotaped interaction task reading and playing with their child. Children will complete brief developmental testing at the beginning of the program.\n\nCaregivers will then complete the PLAY Program, which will involve completing 7 weekly or bi-weekly online modules and meeting with a trained coach by videoconference for up to 10 one-hour sessions over three months. Sessions will focus on helping their child get ready for school and helping their family adjust and cope with stress.\n\nCaregivers will repeat the surveys and videotaped interaction task again three months later, after the PLAY program is completed. They will also be invited to participate in an interview to learn about their experience in the program.\n\nThis study will happen over two phases. Participants in Phase I of this study will complete all parts of the study as described above. Participants in Phase II (beginning in winter 2025) will complete all parts of the study as described above and a six month follow up that will involve repeating the similar questionnaires and an additional videotaped interaction with their child. Teachers of children will also take part in Phase II with questionnaires at baseline and 3-months later, after participants have completed the PLAY program.",[28],[486,487,488,489,490,491],"positive parenting","development","school readiness","digital health","caregiver stress","school advocacy","2025-11-14",{"date":494,"type":38},"2025-11-17",{"date":496,"type":38},"2024-12-12",{"date":498,"type":23},"2027-01-30",{"name":500,"class":45},"Nationwide Children's Hospital",{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":505,"acronym":506,"eligibilityCriteria":507,"healthyVolunteers":12,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":508,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":510,"conditions":511,"keywords":513,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":522,"locationsCount":156},"100418711","the-swiss-childhood-cancer-survivor-study---follow-up-sccss-followup-100418711","NCT04732273","The Swiss Childhood Cancer Survivor Study - Follow-up (SCCSS-FollowUp)","SCCSS-FU","This prospective cohort study is based on the Childhood Cancer Registry (ChCR), a national, population-based cancer registry that includes all children and adolescents in Switzerland who were diagnosed with cancer at age 0-20 years. It includes patients diagnosed with leukemia, lymphoma, central nervous system tumors, and malignant solid tumors or Langerhans cell histiocytosis.\n\nInclusion Criteria:\n\n* Registered in the Childhood Cancer Registry (ChCR) or treated and followed-up in a Swiss pediatric oncology (SPOG) clinic, but not registered in the ChCR because of residency in neighboring countries\n* Diagnosed at age 0 - 20 years\n* Childhood cancer treatment completed\n* All age categories at time of inclusion in the study (children, adolescents, adults)\n* Written informed consent\n\nExclusion criteria:\n\n* Childhood cancer survivors in a palliative or relapsed situation where no follow-up examinations are foreseen.",{"count":509,"type":23},3000,"The SCCSS-FollowUp is a national, multicenter cohort study designed to investigate late effects in childhood cancer survivors in a prospective and longitudinal way. The study is embedded in regular follow-up care and inclusion in the study takes place in a step-wise approach. The investigators collect data from clinical examinations, laboratory and functional tests, and questionnaires to learn more about late effects of childhood cancer treatments.",[512,28],"Late Effect",[28,514,273],"Late Effects","2025-09-18",{"date":517,"type":38},"2025-09-23",{"date":519,"type":38},"2022-06-20",{"date":521,"type":23},"2071-01-01",{"name":44,"class":45},{"id":524,"slug":525,"hasResults":12,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":529,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":19,"minAge":531,"maxAge":77,"enrollmentInfo":532,"targetDuration":4,"studyType":80,"phases":534,"briefSummary":535,"conditions":536,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":541,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":547,"locationsCount":46},"100580630","effect-of-cognitively-challenging-physical-activity-on-executive-functions-in-pediatric-cancer-patients-100580630","NCT06839794","Effect of Cognitively Challenging Physical Activity on Executive Functions in Pediatric Cancer Patients","An Investigator Initiated, Non-randomized Controlled Trial on the Effect of Cognitively Challenging Physical Activity on Executive Functions in Paediatric Cancer Patients","KiKli Fit","Inclusion Criteria:\n\n* Written informed consent of parents \u002F legal guardian and participants, where applicable\n* Diagnosis of any type of cancer requiring chemo- and\u002For radiotherapy, or CNS surgery, expected to last a minimum of at least 6 weeks at the time of recruitment\n* Age: 6-17.99 years at time of recruitment\n\nExclusion Criteria:\n\n* Cognitive and physical disabilities that prevent participation in the intervention.\n* Inability to follow the procedures of the study, e.g. due to language problems.\n* Enrolment of the investigator, his\u002Fher family members, employees and other dependent persons.\n* Denied written informed consent from participants.","6 Years",{"count":533,"type":23},70,[82],"When it comes to exercise and sport for children and adolescents with cancer, there is often still the opinion that physical activity has a negative effect on the weakened body suffering from cancer. Many studies show that the opposite is the case: physical activity for children and adolescents with cancer do not jeopardise the success of treatment, but rather promote it. It has been shown that physical activity has a positive effect on motor skills, physical fitness, sleep quality, fatigue symptoms, body image and general quality of life in children and adolescents with cancer.\n\nIn addition, physical activity leads to an improved fat-to-muscle ratio, metabolic status, bone strength and reduces cardiovascular disease. Furthermore, various studies show that oncological patients with sarcopenia (loss of muscle mass) and frailty have a poorer response to their cancer therapy. This broad spectrum of effects of physical activity leads to improved and faster rehabilitation, is directly linked to the success of treatment and has led to exercise being an integral part of treatment in many paediatric oncology centres worldwide.\n\nFurthermore, more exercise that includes playful cognitive tasks is expected to lead to improved attention, memory and academic achievement. Besides, it is important to try to get children to exercise at home outside of the inpatient setting. Hybrid (on-site and digital meetings) programmes also work for children and adolescents. Additionally, the research project offers sports counselling after the end of therapy to reintegrate the patients into everyday sporting life, be it in a club or at school.\n\nThe central question of the research project is: Does cognitive challenging physical activity developed for children and adolescents undergoing acute cancer therapy improve cognitive and motor performance compared to a control group receiving standard care?",[28,537,538,539],"Cancer-related Problem\u002FCondition","Cognitive Side Effects of Cancer Therapy","Physical Activity","2025-08-11",{"date":542,"type":38},"2025-08-12",{"date":544,"type":38},"2025-05-10",{"date":546,"type":23},"2028-12-01",{"name":44,"class":45},{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":553,"acronym":4,"eligibilityCriteria":554,"healthyVolunteers":18,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":555,"targetDuration":4,"studyType":80,"phases":557,"briefSummary":558,"conditions":559,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":46},"100488580","mobile-app-to-help-survivors-of-childhood-cancer-navigate-long-term-follow-up-care-100488580","NCT05641961","Mobile App to Help Survivors of Childhood Cancer Navigate Long-Term Follow-Up Care","Utilizing a Mobile App to Help Survivors of Childhood Cancer Navigate Long-Term Follow-Up Care","Inclusion Criteria:\n\n* Survivors of childhood cancer attending Survivorship Clinic at University of California, San Francisco (UCSF) OR caregivers of a childhood cancer survivor attending Survivorship Clinic at UCSF.\n* Must have a mobile device (smartphone or smart-tablet) with service plan.\n* Must have ability to read, write, and understand English language.\n\nExclusion Criteria:\n\n* An individual who does not meet any of the criteria mentioned above will be excluded from participation in this study.",{"count":556,"type":23},30,[82],"This clinical trial studies the effectiveness of a newly developed survivorship mobile application (app) designed for survivors, or their caregivers, of childhood cancer to help them better navigate long-term follow-up care. The survivorship app provides survivors access to their treatment history and follow-up recommendations, improves knowledge of their diagnosis, treatment, risks, and recommended follow-up care by using a message notification. The ability to quickly connect and establish care planning may enhance adherence to recommended follow-up.",[28,560,561],"Hematopoietic and Lymphoid Cell Neoplasm","Malignant Solid Neoplasm","2025-07-21",{"date":564,"type":38},"2025-07-23",{"date":566,"type":38},"2022-11-29",{"date":568,"type":23},"2026-04-30",{"name":570,"class":45},"University of California, San Francisco",{"id":572,"slug":573,"hasResults":12,"nctId":574,"briefTitle":575,"officialTitle":576,"acronym":577,"eligibilityCriteria":578,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":77,"enrollmentInfo":579,"targetDuration":4,"studyType":80,"phases":581,"briefSummary":582,"conditions":583,"keywords":585,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":590,"lastUpdatePostDateStruct":591,"startDateStruct":593,"completionDateStruct":595,"leadSponsor":596,"locationsCount":46},"100395788","pictorial-support-in-person-centred-care-for-children-picpecc-100395788","NCT04433650","Pictorial Support in Person-centred Care for Children (PicPecc)","A Person-centred Approach to Pictorial Support in Care for Children (PicPecc)","PicPecc","Inclusion Criteria:\n\n* Children with cancer, 5-17 years\n* The children´s legal guardians\n* Healthcare professionals who take care of these children\n* The child needs to have a cognitive level of approximately five years (i.e., be able to understand a numeric rating scale (NRS)).\n\nExclusion Criteria:\n\n\\- Children 0-4 years",{"count":580,"type":23},40,[82],"Introduction: Person-centred care is based on the assumption that every person has resources that should be used in the care situation. In order for this to happen the patient has to be able to effectively communicate his\u002Fher symptoms. This protocol describes the analysis of a digital picture-based tool for communication support for children with cancer aged 5-17 years, who undergo high-dose methotrexate treatment. The advantage of a non-linguistic based platform, beside the expected clinical outcomes, is that it can be used in multiple national studies with minimal translation.\n\nMethods and analysis: Two studies will be conducted in a hybrid design, i.e., a crossover design will be used for the intervention (effects), and a mixed-methods design will be used for the process evaluation. Qualitative interviews will be carried out with children with cancer, their legal guardians and case-related healthcare professionals as part of the process evaluation.\n\nThe interviews will address the experiences of the intervention and frequency of use from the child's perspective. Interview transcripts will be analyzed qualitative descriptively. The digital communication tool will collect child self-reports of symptoms\u002Femotions. The children will be monitored for biomarkers of stress and pain (neuropeptides, neurosteroids and peripheral steroids) in venous blood samples, in-app estimation levels for the children, drug consumption. Person-centeredness will be evaluated with the questionnaire Visual CARE Measure.\n\nEthics: Ethical approval was obtained from the Swedish Ethical Review Authority (ref 2019-02392; 2020-02601).",[28,584,221],"Communication",[586,584,587,588,589,221],"Childhood cancer","Digital application","Intervention","Pictorial support","2025-04-03",{"date":592,"type":38},"2025-04-06",{"date":594,"type":38},"2021-04-01",{"date":153,"type":23},{"name":597,"class":45},"Göteborg University",{"id":599,"slug":600,"hasResults":12,"nctId":601,"briefTitle":602,"officialTitle":603,"acronym":604,"eligibilityCriteria":605,"healthyVolunteers":12,"sex":19,"minAge":133,"maxAge":134,"enrollmentInfo":606,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":608,"conditions":609,"keywords":611,"overallStatus":251,"whyStopped":4,"lastUpdateSubmitDate":615,"lastUpdatePostDateStruct":616,"startDateStruct":618,"completionDateStruct":620,"leadSponsor":621,"locationsCount":234},"100582876","predict-chimio-or-radiation-induced-nausea-and-vomiting-in-childrenadolescents-treated-for-cancer-100582876","NCT06869005","Predict CHimio-or Radiation-induced NAusea and Vomiting in Children\u002Fadolescents Treated for Cancer","Prévoir Les NAusées Et Vomissements CHimio Ou Radio-induits Chez Les Enfants\u002Fadolescents Traités Pour Un Cancer","PaNACHE","Inclusion Criteria:\n\n* Treated in a pediatric onco-hematology center in the GOCE (Grand Ouest Cancer Enfant) inter-region;\n* Receiving chemotherapy or radiotherapy;\n* According to patient age :\n* Minor (under 18 years): At least one parent has been informed of the protocol and has not expressed opposition to the child's participation in the study\n* Adult (more than 18 years): Having received information about the protocol and not having expressed opposition to participating in the study\n\nExclusion Criteria:\n\n* Patients or legal representatives with French understanding difficulties.\n* Patients or legal representatives subject with legal protection (safeguard of justice, curatorship, guardianship) or deprived of liberty.",{"count":607,"type":23},150,"Chemo- or radiation-induced nausea and vomiting (CRVN) is one of the most frequent and feared side effects.\n\nIt is a symptom that is few or not at all evaluated. There is a significant discrepancy between the perception of the CRVN symptom by caregivers and the patient's own experience.\n\nAt present, there is no real consensus to manage CRVN with medication, and CRVN relief is also the subject of heterogeneous practices. The importance of primary prevention of CRVN, before starting the first treatment sequence, has been highlighted to optimize the action of antiemetic treatments and limit the risk of anticipated nausea and vomiting (NV).\n\nThe investigators' objective is to objectively assess the risk of CRVN in children\u002Fadolescents treated for cancer (and thus effectively prevent this symptom).",[28,610],"Nausea with Vomiting Chemotherapy-Induced",[28,612,613,614],"Chemo- or Radiation-induced Nausea and Vomiting (CVRN),","BARF scale","PaNACHE score","2025-03-06",{"date":617,"type":38},"2025-03-11",{"date":619,"type":23},"2025-03",{"date":256,"type":23},{"name":622,"class":45},"Rennes University Hospital",{"id":624,"slug":625,"hasResults":12,"nctId":626,"briefTitle":627,"officialTitle":628,"acronym":4,"eligibilityCriteria":629,"healthyVolunteers":12,"sex":19,"minAge":630,"maxAge":631,"enrollmentInfo":632,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":634,"conditions":635,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":638,"lastUpdatePostDateStruct":639,"startDateStruct":641,"completionDateStruct":643,"leadSponsor":645,"locationsCount":46},"100581785","siblings-to-a-child-with-cancer-needs-and-pre-loss-grief-100581785","NCT06854822","Siblings to a Child with Cancer: Needs and Pre-loss Grief","Siblings to a Child with Cancer: Psychometric Evaluations of Instruments Assessing Siblings Needs and Pre-loss Grief","Inclusion Criteria:\n\n* Age: 12-24 years\n* Have a brother or sister with childhood cancer\n* Swedish speaking siblings\n\nExclusion Criteria:\n\n-Bereaved siblings","12 Years","24 Years",{"count":633,"type":23},200,"Background and Aim: Siblings to a brother or sister with cancer have reported difficulties dealing with such things as their parents' suffering, loneliness in relation to their own feelings as well as uncertainty regarding their brother's\u002Fsister's treatment, prognosis and survival. Siblings also struggle with fear of death and dying, and unresolved grief. Unfortunately, siblings are a forgotten group both in society, within the family, in health care, in school, and in research even if there has been a huge improvement the last 10 years. These children's needs must be identified and handled during the illness trajectory as a way of supporting their challenging situation and prevent avoidable psychological distress. Nevertheless, there exists no validated standardized assessment instrument in Swedish that measure the needs of these children even if it is well known that it is beneficial for emotional and psychological well-being to use assessment instrument. Moreover, no instrument in Swedish exists that identify children with prolonged pre-death grief despite that prolonged grief during illness is associated with psychological distress. This study therefore aim to translate, culturally adapt, and evaluate the psychometric properties of the Swedish version of the Sibling Cancer Needs Instrument (SCNI) and Prolonged Grief Disorder (PG-12) among children and youths who have a brother or sister with cancer.\n\nMaterial and Methods: Present instruments will be translated and culturally adapted according to the World Health Organization's (WHO) guidelines. After that, the psychometric properties of the Swedish version of SCNI and PG-12 will be examined. The Swedish version of the SCNI and PG-12 will be revised by a group of several experts in psychology, paediatric oncology, and family health, for its face and content validity. In addition, pre-test respondents will include approx. 10 siblings. They will be recruited from one of the six pediatric oncology centers in Sweden, the home care for children at the same hospital, and at the hospice for children and youths in Sweden (Lilla Erstagården) where established collaborations with clinicians exists today with sibling supporters. Information about the study will be given by the researchers who also ask for informed consent. Children aged 15 years and older consent themselves while those between 12-14 years have to have consent from their guardian(s)\u002Fparent(s). Pre-test respondents will be administered SCNI and PG-12 and be systematically debriefed. During debriefing, siblings will be asked what they thought the question was asking, whether they could repeat the question in their own words, what came to their mind when they heard a particular phrase or term. They will also be asked to explain how they choose their answer. These questions will be repeated for each item. The answers to these questions should be compared to the respondent's actual responses to the instrument for consistency. Respondents will also be asked about any word they did not understand as well as any word or expression that they found unacceptable or offensive. Finally, when alternative words or expressions exist for one item or expression, the pre-test respondent should be asked to choose which of the alternatives conforms better to their usual language. After that, siblings will be asked to participate in a web-survey. They will be recruited from: 1) the six pediatric oncology centers in Sweden, 2) the hospice for children and youths in Sweden (Lilla Erstagården), and 3) via advertisement on social media, e.g. on Instagram at \"Nära Cancer\" and the Childhood Cancer Fund. The siblings will also be identified by a sibling supporter at the six pediatric oncology centers and Lilla Erstagården. The sibling supporters will invite the siblings to the study by giving them a web address to a website where they will find information about the study. On the website, the siblings could either go directly to the web-survey (if the sibling is 15 years or older) or register their interest to participate in the web-survey (if the sibling is between 12-14 years). Parents of siblings who register their interest to participate in the web-survey on the website (siblings aged 12-14 years), will be contacted by a researcher via email or phone (depending on how they wish to be contacted), and the parents\u002Fguardians and the sibling will be informed about the study, and informed consent will be granted from both guardians\u002Fparents. Advertisement on social media will take the siblings or parents\u002Fguardians to the same web-page\u002Fweb-survey as previously described.\n\nAnalysis: Descriptive statistics will be used to present demographic data and study variables, including means and standard deviations, medians and quartiles, and frequencies. We will use factor analysis in order to evaluate the fit of the models. A sample size of 200 will be acceptable if the models are not too complex.",[28,636,637],"Siblings","Psychosocial Functioning","2025-03-03",{"date":640,"type":38},"2025-03-05",{"date":642,"type":23},"2025-03-01",{"date":644,"type":23},"2026-03-01",{"name":646,"class":45},"Ersta Sköndal University College",{"id":648,"slug":649,"hasResults":12,"nctId":650,"briefTitle":651,"officialTitle":651,"acronym":4,"eligibilityCriteria":652,"healthyVolunteers":12,"sex":19,"minAge":394,"maxAge":653,"enrollmentInfo":654,"targetDuration":656,"studyType":25,"phases":4,"briefSummary":657,"conditions":658,"keywords":659,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":664,"lastUpdatePostDateStruct":665,"startDateStruct":667,"completionDateStruct":669,"leadSponsor":671,"locationsCount":124},"100282634","shanghai-epidemiology-study-for-adolescents-and-children-with-cancer-100282634","NCT02959086","Shanghai Epidemiology Study for Adolescents and Children with Cancer","Inclusion Criteria:\n\n* 0-19 year-old children and adolescents.\n* Diagnosed cancer in Shanghai since January 2002.\n\nExclusion Criteria:\n\n* Patients who were lost of follow-up.\n* Patient's death wasn't caused by cancer or complications but by other accidents such as car accident, fell from a great height and so on.","19 Years",{"count":655,"type":23},2000,"10 Years","The purpose of this study is to describe the morbidity, mortality, disability and survival rate in Shanghai adolescents and children with cancer diagnosed since January 2002.",[28],[660,661,112,662,663],"Epidemiology","Shanghai","Adolescents","Children","2025-02-11",{"date":666,"type":38},"2025-02-13",{"date":668,"type":38},"2002-01",{"date":670,"type":23},"2030-01",{"name":672,"class":673},"Children's Cancer Group, China","NETWORK"]